Media Summary: Our Chief Medical & Scientific Officer Dr Carol Routledge, discusses some of the key highlights from our Dr. David Erritzoe, Chief Investigator of MindMed finds a promising comparison between LSD and psilocybin;
Small Pharma S Spl026 Phase - Detailed Analysis & Overview
Our Chief Medical & Scientific Officer Dr Carol Routledge, discusses some of the key highlights from our Dr. David Erritzoe, Chief Investigator of MindMed finds a promising comparison between LSD and psilocybin; Dr. Carol Routledge, Chief Medical & Scientific Officer of Dr Alastair Riddell, Chief Operating Officer at Dr. Carol Routledge, Chief Medical and Scientific Officer at
In what is another giant step forward for the psychedelic therapeutics community, the UK-based neuropharmaceutical brand Ellen James, PhD, Director of Research and Development, Investors in the psychedelics space may have only just heard of the UK-based Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief ... Dr. David Erritzoe, Consultant Psychiatrist, has worked with many patients throughout his career. He shares some observations on ... Who's behind $DMT and what are their goals and opportunities? Peter Rands,
